Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPC and AGE Levels in ER+ Metastatic Breast Cancer
NCT03092635Phase 1Terminated
- Sponsor
- Medical University of South Carolina
- Start
- Jun 2017
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of opicapone in breast cancer, sponsored by Medical University of South Carolina. Primary endpoint: Advanced Glycation Endproduct reduction at 85 days. Started Jun 2017; status: terminated.
02
Drugs
opicapone
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03092635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03092635.